Bifunctional peptide having capability to permeate cells and capability to regenerate muscles and use thereof

Patent metadata

Field	Value
Publication number	US-2019284306-A1
Application number	US-201916297864-A
Country	US
Kind code	A1
Filing date	Mar 11, 2019
Priority date	Mar 14, 2018
Publication date	Sep 19, 2019
Grant date	—

Abstract

Disclosed are a bifunctional peptide having the capability to permeate cells and the capability to regenerate muscles and the use thereof. Advantageously, the bifunctional peptide has a function of regenerating muscle cells and thus is useful for the prevention or treatment of diseases affecting muscle regeneration, and additionally has the capability to permeate cells and thus eliminates the necessity to adhere an additional peptide or add other agent or drug for cell permeation of the peptide, thereby finally exerting an efficient muscle generation effect. Thus, the bifunctional peptide can be easily applied to various surgical regenerative treatments and can shorten the treatment period.

First claim

What is claimed is:

1 . A method for preventing or treating a muscle disease, comprising administering a bifunctional peptide represented by an amino acid sequence of any one of SEQ ID NOS: 1 to 8.

2 . The method according to claim 1 , wherein the peptide is a bifunctional peptide having a capability to permeate cells and a capability to regenerate muscles.

3 . The method according to claim 1 , wherein the peptide facilitates differentiation of stem cells into myocytes.

4 . The method according to claim 1 , wherein the muscle disease is selected from the group consisting of muscular dystrophy, muscular atrophy, muscular sarcopenia, myositis, polymyositis, peripheral vascular disease and fibrosis.

5 . The method according to claim 1 , wherein the peptide is prepared for oral administration, injection or topical implantation.

6 . The method according to claim 1 , wherein the peptide is administered at a dose of 0.001 to 1,000 mg per 1 kg of a body weight of a subject in need of treatment.

7 . A tissue-engineering scaffold for treating a muscle disease comprising a peptide represented by an amino acid sequence of any one of SEQ ID NOS: 1 to 8.

8 . The tissue-engineering scaffold according to claim 7 , wherein the peptide is a bifunctional peptide having a capability to permeate cells and a capability to regenerate muscles.

9 . The tissue-engineering scaffold according to claim 7 , wherein the tissue-engineering scaffold comprises any one selected from the group consisting of collagen, gelatin, fibrin gel, alginate and hyaluronic acid.

10 . The tissue-engineering scaffold according to claim 7 , wherein the peptide is administered at a dose of 0.001 to 1,000 mg per 1 kg of a body weight of a subject in need of treatment.

11 . A method for treating a muscle disease using a tissue-engineering scaffold comprising a peptide represented by an amino acid sequence of any one of SEQ ID NOS: 1 to 8.

12 . The method according to claim 11 , wherein the peptide is a bifunctional peptide having a capability to permeate cells and a capability to regenerate muscles.

13 . The method d according to claim 11 , wherein the tissue-engineering scaffold comprises any one selected from the group consisting of collagen, gelatin, fibrin gel, alginate and hyaluronic acid.

14 . The method according to claim 7 , wherein the peptide is administered at a dose of 0.001 to 1,000 mg per 1 kg of a body weight of a subject in need of treatment.

Assignees

• Seoul Nat Univ R&Db Foundation
• Nano Intelligent Biomedical Eng Corporation Co Ltd

Inventors

• Park Yoon Jeong
• Chung Chong-Pyoung
• Lee Jue-Yeon

Classifications

• C07K19/00 Primary

  Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes} · CPC title

• A61P21/00

  Drugs for disorders of the muscular or neuromuscular system · CPC title

• A61L27/222

  Gelatin · CPC title

• A61K35/34

  Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes (vascular smooth muscle A61K35/44) · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title